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Abstract
The NHS needs valid information on the safety and effectiveness of healthcare interventions. Cochrane systematic
reviews are an important source of this information. Traditionally, Cochrane has attempted to identify and include
all relevant trials in systematic reviews on the basis that if all trials are identified and included, there should be no
selection bias. However, a predictable consequence of the drive to include all trials is that some studies are
included that are not trials (false positives). Including such studies in reviews might increase bias. More effort is
needed to authenticate trials to be included in reviews, but this task is bedevilled by the enormous increase in the
number of ‘trials’ conducted each year. We argue that excluding small trials from reviews would release resources
for more detailed appraisal of larger trials. Conducting fewer but broader reviews that contain fewer but properly
validated trials might better serve patients’ interests.
Background
The UK National Institute for Health Research (NIHR)
provides public funding for systematic reviews because
the information they provide informs healthcare decision
making in the NHS and the commissioning of new re-
search. For both purposes, it is essential that the infor-
mation reviews provide is valid and up-to-date. In
October 2015, NIHR announced an evaluation of its
investment in Cochrane infrastructure for the produc-
tion and dissemination of reviews. It will consider the
health and economic impact of Cochrane reviews by
‘assessing the quantity, quality and impact of reviews on
policy, practice and research’. Of the parameters assessed
(quantity, quality, impact), quality is the most important.
Systematic reviews will not bring health and economic
benefits if their conclusions are misleading. We consider
the main threats to validity in systematic reviews and
how they can be minimised cost-effectively.
The conclusions of a systematic review can be mis-
leading if it includes a biased sample of trials (selection
bias in study identification and inclusion) and/or the ef-
fect estimates in the included trials are biased. Validity
requires an unbiased sample of unbiased effect esti-
mates. Neither criterion is easy to satisfy. About half of
all trials are not published, and the results of published
and unpublished trials differ systematically [1, 2]. Even if
all trials could be identified, selective reporting of out-
comes remains an important source of bias [3]. Because
of poor methodology, the results of many trials are
biased, and incomplete or inaccurate reporting of trial
methods frustrates quality assessment.
Find all the trials
Since its inception, Cochrane has attempted to avoid
selection bias in study identification and inclusion by
conducting exhaustive searches for all trials, published
or unpublished, irrespective of language of publication.
If all trials are included, there should be no such selection
bias. A ‘highly sensitive search strategy’ was developed to
identify all trials in the main electronic bibliographic data-
bases [4]. Because many trials in indexed journals were not
coded as such by the National Library of Medicine, trial
identification was supplemented by hand-searching. This
resulted in a major initiative to re-tag records that were not
properly coded. The Cochrane Central Register of Con-
trolled Trials (CENTRAL) launched in 1996 includes trials
identified in electronic databases and by hand-searching [5,
6]. Trial identification has become a highly specialised ac-
tivity, and almost all Cochrane Groups have a dedicated
trial search co-ordinator to undertake this role. However,
despite extensive efforts to identify and include all relevant
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trials, selection bias (in study identification and inclusion)
still casts doubt on the conclusions of many reviews.
The problem of false positives
A predictable consequence of the drive to find and
include all trials is that some studies are included that
are not trials (false positives). Maximising sensitivity often
decreases specificity. Many reports claiming to be ‘rando-
mised trials’ are not in fact randomised, often owing to a
lack of an understanding of trial design among the authors
and sometimes due to downright deception. An interview
study of Chinese authors of so-called randomised con-
trolled trials found that only 7 % were authentic [7]. Even
for trials conducted at university-affiliated hospitals, only
56 % were authentic [7]. Although it would be inappropri-
ate to assume that the prevalence of ‘false positives’ is as
high in other settings, it would also be inappropriate to
ignore these findings and take trials at face value without
conducting further checking.
Meta-analyses of baseline variables in systematic reviews
of randomised trials often reveal surprising imbalances
suggesting that randomisation was either subverted or ab-
sent [8, 9]. And some reviews contain fraudulent data. A
Cochrane review showing that high-dose mannitol reduced
the risk of death after head injury was rewritten after an in-
vestigation was unable to confirm that three of the included
trials took place [10]. The conclusions of a review of starch
solution in critically ill patients changed importantly after
excluding seven ‘trials’ from an investigator whose research
was retracted due to misconduct [11, 12]. Many journal edi-
tors and systematic reviewers take trial reports at face value
with little or no effort to confirm whether a trial actually
took place or how reliably it was conducted. A recent sur-
vey of authors of systematic reviews found that 38 % had no
contact with the authors of the original studies [13]. Indeed,
the amount of contact with authors is rarely reported in
reviews. Checking with ethics committees that ethical
approval was obtained for a trial is one of the few ways to
obtain independent confirmation that a trial took place and
even then is not completely reliable. However, very few
(3 %) reviewers check whether the included studies had
such approval [13]. Unless sensitive searching is ac-
companied by similarly rigorous efforts to ensure the
integrity of the included trials, the precision gained by
including a larger number of ‘trials’ could be out-
weighed by an increase in bias.
NIHR funding for Cochrane Groups is proportional to
the number of reviews published and the number of tri-
als included in reviews. Both criteria have seriously det-
rimental unintended consequences. First, it incentivises
the fragmentation of evidence. For example, there are
over 100 Cochrane reviews on the treatment of hyper-
tension, including separate reviews of treatment trials in
people with and without diabetes, rather than a single
review assessing whether diabetes is an effect modifier.
Second, there is a financial incentive to include every
study purporting to be a ‘trial’ with no incentive to root
out false positives.
The challenge of validating trials
Unless rigorous efforts to identify trials are accompanied
by at least as much effort to assess their integrity and
completeness, extensive searching may have the unin-
tended consequence of reducing the reliability of reviews.
Results from individual patient data meta-analyses are
likely to be more reliable in this respect since they
involve checking the integrity and completeness of all
included data. However, they can be challenging and
costly and are not immune from selection bias [14].
Nevertheless, simpler checks are possible. We believe
that authors should be required to provide evidence
that the trial actually took place and that the partici-
pants were properly randomised, that there were no
post-randomisation exclusions and no selective report-
ing. This could be combined with the use of software
to detect plagiarism and statistical data checking (e.g.
detection of extreme between study homogeneity).
Reviews should routinely report their validation strat-
egies, including which trials were confirmed and which
authors were unresponsive.
However, the task of identifying and authenticating all
potentially relevant trials is bedevilled by the enormous
increase in the number of ‘trials’ conducted each year
(Fig. 1). In 1993, the year the Cochrane Collaboration was
founded, 823 trials were indexed in PubMed. Twenty-two
years later, the corresponding figure is 9673 trials. If ef-
forts to prevent bias through the complete ascertainment
of trials have failed to date, it is unlikely they will succeed
in future without a considerable increase in resources.
Many Cochrane reviews are already out-of-date and the
situation can only be expected to get worse.
Small trials—are they worth the effort?
Most trials are small. Over half of registered trials in-
clude fewer than 100 participants (Fig. 2). Many import-
ant health outcomes (death, myocardial infarction,
stroke, sepsis, pneumonia) are dichotomous and occur
in only a small proportion of trial participants. Most
small trials register only a few such outcome events in
each arm. With such sparse outcome data, there is a
substantial risk of selective under-reporting of trials and
patient outcomes. This is a major threat to validity. One
fifth of Cochrane meta-analyses with a statistically sig-
nificant result became non-significant after adjusting for
outcome reporting bias [3].
Meta-epidemiological studies show that small, single-
centre trials generally provide larger estimates of treat-
ment effects than large, multi-centre trials [15–18]. This
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could be due to strict patient selection and better inter-
vention compliance in small trials. However, it is often
due to the poor quality of small trials and their greater
risk of selection bias. Furthermore, small trials that are
stopped early for apparent benefit often provide im-
plausibly large effects (the overestimates are smaller in
large trials) [19, 20]. Random effects models exacerbate
small study bias. In the presence of heterogeneity, ran-
dom effects models give greater weight to small studies,
which are more susceptible to bias. Small studies with
large effects appear to ‘anchor’ the meta-analysis such
that the result is largely unchanged regardless how large
the subsequent trials. When meta-analyses are restricted
to larger studies, treatment effects that appear large and
statistically significant when all trials are combined usu-
ally become smaller [16]. This suggests that including all
apparent trials in systematic reviews can increase rather
than decrease bias.
The well-documented unreliability of small trials offers
an opportunity to increase the validity of reviews whilst
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Fig. 2 Number of prospectively and retrospectively registered randomised trials of drug interventions started since the introduction of ICMJE’s
registration policy in July 2005, stratified by sample size
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reducing the burden and cost of conducting and main-
taining them. Although large trials provide more infor-
mation about the treatment effect than small trials, the
time and effort required to evaluate a trial is often
inversely related to sample size. Limiting inclusion to
larger trials would release resources that could be redir-
ected to a more thorough critical appraisal of the trials
that provide the most information. The sample size cut-
off would clearly depend on the objectives of the review
and the outcomes of interest. The information content of
a trial depends on the number of events rather than the
number of participants. Quantitative research is needed
on the sample size cut-off that would provide an optimal
balance of sensitivity and specificity, and on other markers
of unreliable data.
The exclusion of grossly underpowered trials from sys-
tematic reviews and meta-analyses should reduce bias, but
it is not a guarantee. A more reliable approach would be
to identify trials for inclusion in systematic reviews from
trial registers [21]. Systematic reviews that entail complete
ascertainment of results from all (or an unbiased sample
of) prospectively registered trials (i.e. trials registered
before the first patient is enrolled) should not be affected
by selection bias in trial identification and inclusion. In-
deed, preventing such selection bias is one of the main
purposes of registers, and trials with large sample sizes are
more likely to be prospectively registered (Fig. 2). How-
ever, including only prospectively registered trials is not
sufficient. Trials that were prospectively registered but not
reported must be sought out and included to avoid bias.
Similarly, data on health outcomes that were collected but
not fully reported must be pursued and included. This will
take time and effort and will be greatly facilitated by
excluding the myriad small trials that provide negligible
amounts of information.
Counter arguments
Some argue that including all trials, regardless of size or
quality, allows reviewers to draw attention to the scandal
of low-quality, underpowered trials [22]. We agree that
the main contribution of systematic reviews has been to
highlight the miserable unreliability of most biomedical
research. However, in the light of the methodological
advances from meta-epidemiological studies, it is ques-
tionable whether highlighting poor quality remains a
legitimate use of public funds. Indeed, including such
trials in reviews gives them unwarranted endorsement.
Another argument for including small trials in reviews
is that the combined results from small trials often
motivate larger high-quality studies. For example, Chal-
mers and Glasziou argue that ‘funders and regulators
cannot be expected to support and endorse large studies
without some reassurance from the results of smaller
existing studies that the substantial investment needed is
justified’ [23, 24]. Whilst we agree that investment in
new research should be preceded by systematic assess-
ment of existing evidence, it is essential to avoid making
funding decisions that are heavily influenced by biased
research. Because effect estimates from systematic reviews
often inform sample size calculations, there is a danger
that inflated effect estimates from reviews of small trials
motivate new trials that are underpowered to detect realis-
tic treatment effects. For example, a Cochrane review of
randomised trials of the effect of preoperative statins on
the risk of post-operative atrial fibrillation included 17
small trials with a total of 2138 participants and reported a
halving of the odds of post-operative atrial fibrillation with
statin treatment (OR = 0.54; 95 % CI 0.43 to 0.67; p < 0.01)
[25]. This claim was later refuted by a randomised trial
(the Statin Therapy in Cardiac Surgery (STICS) trial) that
included more outcome events (cases of atrial fibrillation)
than all the previous trials combined that found no reduc-
tion in atrial fibrillation (OR = 1.04; 95 % CI 0.84 to 1.30;
p = 0.72) [26]. Fortunately, the STICS trial investigators
were appropriately sceptical of the large treatment benefits
suggested by the Cochrane review of small trials and con-
ducted a trial with sufficient power to exclude a more
plausible effect. However, although the new trial appears
to refute the conclusion of earlier smaller trials because of
the anchoring effect of small studies with large treatment
effects, the updated meta-analysis will still suggest a
significant reduction in atrial fibrillation with statin treat-
ment, a conclusion that seems unlikely.
Conclusion
The NHS needs valid information on the safety and ef-
fectiveness of healthcare interventions. This information
must be provided cost-effectively. Although investment
in systematic reviews can be more cost-effective than
conducting new trials, this should not rule out consider-
ation of how to improve the cost-effectiveness of con-
ducting reviews. We argue that attempting to identify
and include all apparently relevant trials might increase
rather than decrease bias and may not be the most cost-
effective approach. Many supposed ‘trials’ are not in fact
randomised trials. The gulf between individual partici-
pant data meta-analyses, where all data is thoroughly
checked for accuracy and completeness, and systematic
reviews based on published data from apparent trials is
too wide. More effort is needed to validate trials and
obtain data on unreported outcomes. Excluding grossly
underpowered small trials from reviews might increase
validity and release resources for more detailed appraisal
of included trials. NIHR incentives to conduct narrowly
focused reviews including everything purporting to be a
trial should be re-considered. Incentives to conduct
fewer but broader reviews that contain fewer but prop-
erly validated trials might better serve patients’ interests.
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